
    
      This clinical study is phase 1/2a clinical trial to evaluate safety, tolerability, and
      immunogenicity of COVID-19 preventive vaccine by intramuscularly administration in healthy
      volunteers.

      Phase 1 of this study is designed as single arm, open-labeled and a total of 20 subjects will
      be enrolled. Phase 2a of study is designed as randomized, double-blind, placebo controlled
      and a total of 150 subjects are planned to be enrolled.
    
  